Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 24Squamous Cell Carcinoma of Head and Neck 11Small Cell Lung Carcinoma 11Lung Neoplasms 11Neoplasm Metastasis 10Carcinoma, Hepatocellular 9Breast Neoplasms 9Pancreatic Neoplasms 8Ovarian Neoplasms 8Colorectal Neoplasms 8Triple Negative Breast Neoplasms 7Advanced Solid Tumors 7Melanoma 6Biliary Tract Neoplasms 6Urinary Bladder Neoplasms 5Cholangiocarcinoma 5Uterine Cervical Neoplasms 4Prostatic Neoplasms 4Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Carcinoma, Renal Cell 4Stomach Neoplasms 3Recurrence 3Multiple Myeloma 3Head and Neck Neoplasms 3Diabetes Mellitus, Insulin-Dependent, 12 3Advanced Solid Tumours 3Vulvar Neoplasms 2Vaginal Neoplasms 2Solid Tumor 2

Interventions

tremelimumab 1ixabepilone 1durvalumab 1ST 1481 1Paclitaxel 1Fulvestrant 1Docetaxel 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Solid Malignancies × durvalumab × Clear all
NCT02537418 2026-03-27

Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

Canadian Cancer Trials Group

Phase 1 Active not recruiting
153 enrolled

Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡